Background: Rates of postpartum haemorrhage and atonic postpartum haemorrhage have increased in several high-income countries. We carried out a study to examine if drug use in pregnancy, or drug and other interactions, explained this increase in postpartum haemorrhage.
However, many of these investigations used large population-based data sets with inadequate detail on pre-pregnancy weight and labour management. Therefore, it remains unclear whether temporal increases in atonic PPH represent true increases in haemorrhage due to changes in maternal characteristics, obstetric practice or other extraneous factors, or artefacts due to subtle changes in the diagnosis of this difficult to diagnose condition.
Nevertheless, the failed attempts at explaining the recent increase in atonic PPH have led to the aetiologic focus shifting from maternal and obstetric factors to potential drug effects and drug interactions. 9 The absence of reports of temporal increases in atonic PPH from low-and middle-income countries (which are less medicalised) also raises the possibility of a drug effect or drug interaction. The use of pharmaceutical agents in pregnancy including selective serotonin reuptake inhibitors (SSRIs), aspirin, and other antiplatelet drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and antihistamines has increased in high-income countries in recent decades, [15] [16] [17] [18] and studies have shown increased rates of bleeding associated with the use of some of these agents either singly or in combination. [19] [20] [21] Drug interactions and interactions between drugs and specific medical conditions (such as alcoholism, liver disease, and thrombocytopenia) are other potential explanations for increases in rates of atonic PPH. We therefore carried out a population-based study examining the effects of the above-mentioned drugs and medical conditions on rates and temporal trends in PPH.
Methods
This population-based study was carried out using the linked administrative database of the Québec Pregnancy Cohort. 22 This database is the product of a linkage of the physician claims database (Régie de l'assurance maladie du Québec, the RAMQ database), the hospitalisation database (the MED-ECHO database), and the vital statistics database (Institut de la statistique du Québec, the ISQ database) in Québec, Canada. The prescription claims component of the RAMQ database included prospectively collected data on prescriptions filled by recipients of social assistance, and workers and their families who did not have access to a private drug insurance plan (in Québec all citizens are insured for physician visits and hospitalisations, whereas recipients of social assistance and workers and their families who do not have access to a private drug insurance are also insured for outpatient drug costs); 36% of women between 15-45 years in Québec were included in such coverage. 22 The MED-ECHO database recorded acute care hospitalisation data for all Québec residents. Information on hospitalisations for childbirth, including maternal characteristics, gestational age at delivery, and diagnoses and procedures was included in the database. 22 Gestational age in the Québec Pregnancy Cohort was defined as the duration between the first day of the last menstrual period and delivery, confirmed by ultrasound. The vital statistics database included information on all live births and stillbirths. Pregnancy-related variables in the cohort, such as birth weight, gestational age, and date of delivery, as well as specific International Classification of Diseases (ICD) codes, have been previously validated against patient charts. 23, 24 Prescription information in the Québec Pregnancy Cohort has also been validated, and pregnant women covered by the RAMQ for their medications have co-morbidity profiles similar to pregnant women insured by a private medication insurance plan. 23 Information on women in the cohort included data from the date of entry into the cohort (i.e. the first day of the last menstrual period confirmed by ultrasound), through pregnancy and also the early postpartum period.
Study population
The study base was a dynamic population of women in Québec with a gestational age of 20 weeks or greater between 1 January 1998 and 31 December 2009 who were continuously insured by the RAMQ drug plan for at least 12 months prior to and during pregnancy. For each pregnancy, data on all filled prescriptions in the year preceding and during pregnancy including the date of filling the prescription, drug name, dosage, form, quantity, and duration were obtained. Data were also obtained on all inpatient and ambulatory medical services, including physician diagnoses made before and during pregnancy and in the immediate postpartum period.
classification (as opposed to the alternative cohort design with time windows anchored to cohort inception). 25 This permitted the assessment of drug effects in women with recent drug exposure (i.e. in the month before childbirth when PPH did or did not occur) or past drug exposure. We attempted to carry out three primary base type case-control studies 26 within the study base (defined above) in order to examine the relationship between the drugs and specific medical conditions of interest and PPH. The outcomes of interest in the three case-control studies were (i) any PPH, (ii) atonic PPH, and (iii) severe atonic PPH.
Case definition
PPH in Canada is defined as a postpartum blood loss of ≥500 mL following a vaginal delivery, a postpartum blood loss of ≥1000 mL following a caesarean delivery or as diagnosed by the health care provider in the medical chart. For the case-control study on any PPH, all women whose pregnancies ended in a live birth or stillbirth and who had any type of PPH (i.e. an ICD-9 diagnosis code of 6660, 6661, 6662 or 6663 or an ICD-10 diagnosis code of O720, O721, O722, O723) were considered cases (secondary scheme of case ascertainment 26 ). The second case-control study defined cases as women whose pregnancies ended in a live birth or stillbirth and who had atonic PPH (an ICD-9 diagnosis code of 6661 or an ICD-10 diagnosis code of O721). For the third case-control study, cases were defined as women whose pregnancies ended in a live birth or stillbirth and who had severe atonic PPH. However, absence of information on medical interventions in a substantial fraction of the study population (including information on blood transfusion and procedures to control bleeding) precluded us from carrying out this study on severe atonic PPH. The index date was defined as the date of delivery for all analyses.
Control definition
Controls for the first case-control analysis were identified from among women without PPH. Up to five controls were randomly selected for each case after matching on index date (+/− 1 month) and the hospital in which the delivery occurred (incidence density sampling). Because cases in the second case-control study (on atonic PPH) were a subset of the cases in the first case-control study (on any PPH), the appropriate subset of the controls selected for the first study served as the controls for the second case-control study.
Maternal use of drugs
Medications of interest included (i) SSRIs and other antidepressants (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, phenelzine, tranylcypromine, amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, trimipramine, bupropion, buspirone, maprotiline, l-tryptophane, mirtazapine, trazodone, and moclobemide), (ii) aspirin (any dose), (iii) other antiplatelet drugs: (clopidogrel, aggrenox, dipyridamole), (iv) NSAIDs and Cox-2 inhibitors (celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbirofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefanamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tiaprofenic acid, tolmetin, and valdecoxib), (v) beta-agonists (salbutamol, levosalbutamol, terbutaline, salmeterol, and formoterol), and (6) antihistamines (diphenhydramine, dimenhydrinate, and doxylamine). Identification of drug use was limited to prescription-drug use, and over-the-counter use of drugs such as aspirin and NSAIDs was not studied.
Drug use was examined in the 6 months before the index date (date of delivery). Within this time window, two mutually exclusive sub-windows were also examined, namely, (i) past use (drug use 180 days to 31 days before the index date), and (ii) recent use (drug use within 30 days prior to the index date). The two different time windows for drug exposure were studied in order to explore immediate and more remote effects of the drugs of interest and to evaluate the biologic plausibility of any observed effects.
stage, caesarean delivery, uterine rupture, cervical laceration, severe perineal tear, and chorioamnionitis.
Statistical analyses
Temporal trends in PPH and atonic PPH in the study population were assessed. Unadjusted and adjusted odds ratios were obtained from conditional logistic regression analyses of the two case-control studies and interpreted as incidence density rate ratios with 95% confidence intervals (CI). 27, 28 For each casecontrol study, the adjusted models included three different sets of variables. The first model in each case-control study estimated the effect of each drug (antidepressants, aspirin, other antiplatelet drugs, beta-agonists and antihistamines) and each co-morbidity (alcoholism, liver disease, thrombocytopenia and asthma), along with year of delivery. Since conditional logistic regression only precludes estimation of the effect of matching variables that have exactly the same value for all members of a matched set, 29 we were able to estimate the effect of year of delivery, which was of a priori interest; differing values for 'month of delivery' (the matching variable used for incidence density sampling) and 'year of delivery' occurred in approximately one sixth of our matched sets when the month of delivery was January or December of any year. The second model additionally included maternal and obstetric risk factors, whereas the third model included all variables in the second model plus interaction terms (for combined antidepressant and aspirin use, combined betaagonist and aspirin use, combined aspirin use and thrombocytopenia, and combined antidepressant use and thrombocytopenia). The population attributable fraction expressing the impact of drugs and co-morbidity was estimated based on the frequency of drug use/co-morbidity among the cases and the adjusted rate ratio (aRR) for their effect on PPH. 30 
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Results
The study population included 138 704 deliveries that satisfied eligibility criteria for admission into the Table 1 ]. The same unexpected non-linear decline was evident in rates of atonic PPH (Table 1) , although the rate in 2009 was again slightly higher than the rate in 1998 ( Figure 1) .
A total of 6378 cases and 31 795 controls were available for analysis in the case-control study on any PPH. Year of delivery was associated with a decline in PPH [unadjusted rate ratio 0.99, 95% CI 0.99, 1.00]. Table 2 shows unadjusted rate ratios expressing the association between maternal drug use and other risk factors and PPH. Any use, past use, and recent use of Drug effects and increases in postpartum haemorrhage 223 antidepressants were associated with an increase in PPH. Several maternal and obstetric factors were associated with increases in PPH, including receipt of social assistance, multi-foetal pregnancy, placenta previa/abruption, prolonged labour, pre-eclampsia, epidural analgesia, labour induction, severe perineal laceration, uterine rupture, cervical laceration, high vaginal laceration, chorioamnionitis, and thrombocytopenia during the delivery hospitalisation or during the pregnancy and delivery hospitalisation. Previous caesarean delivery and caesarean delivery were the only protective factors (Table 2) . Table 3 shows the results of conditional logistic regression with unadjusted and aRRs expressing the relationship between variables in the first model (which included year of delivery, any use of specific drugs and specific co-morbid conditions) and the second model (which included year of delivery, any drug use, specific co-morbidity, and maternal and obstetric factors) and any PPH. In the latter model, which adjusted for maternal and obstetric factors, Drug effects and increases in postpartum haemorrhage 225 fraction for antidepressant use was 0.78% (i.e. <1% of PPH would be prevented if women stopped using antidepressants in pregnancy), whereas the population attributable fraction for thrombocytopenia was 0.37%. Concurrent exposure to antidepressants and aspirin, beta-agonists and aspirin, aspirin and thrombocytopenia, or antidepressants and thrombocytopenia was associated with higher rates of PPH, although none of these interactions were statistically significant (see interaction terms, Table 3 ). Adjustment for drug use, co-morbidity, and drug and other interactions (in addition to maternal and obstetric factors) did not alter the temporal trend in any PPH. Similar results were obtained in analyses on atonic PPH. Table 4 shows the unadjusted rate ratios for drug use, specific morbidity, and maternal and obstetric factors. The factors associated with atonic PPH were similar to those associated with any PPH. Results of adjusted analyses were also similar ( 
Comment
Our studies showed expected associations between maternal and obstetric factors and postpartum and atonic PPH. Among the drug classes and co-morbidity studied, only antidepressants and thrombocytopenia were associated with an increased risk of PPH. Interactions between antidepressants, aspirin, betaagonists and thrombocytopenia were not significant and temporal trends in PPH and atonic PPH were not changed by controlling for medication use, maternal characteristics and obstetric factors.
The absence of a temporal increase in PPH and atonic PPH in our study was surprising given the increases noted in other high-income countries. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] One potential explanation for this phenomenon relates to the dynamic nature of our study population. Eligibility was dependent on inclusion in the RAMQ prescription database, which was restricted to recipients of social assistance, and workers and their families who did not have access to a private drug insurance plan. It is possible that temporal changes in the types of women who satisfied these socioeconomic criteria for entry into and exit from this population were responsible for the absence of an increase in atonic PPH. On the other hand, the rates of PPH and atonic PPH observed in our study were similar to rates observed elsewhere in Canada and in other countries such as Australia, Ireland, and Sweden (although the rates were higher than those observed in some Canadian provinces and the US). [1] [2] [3] [4] 7, 9, 12 Variation in international rates of PPH is not unexpected because accurate estimation of blood loss during childbirth represents a clinical challenge; diagnostic idiosyncrasies may be partly responsible for spatial differences in rates of PPH.
Numerous case reports and epidemiologic studies show an increased risk of bleeding associated with the use of SSRIs; the most common bleeding risk described has been a doubling of the rate of upper gastrointestinal bleeding. 31, 32 However, few studies have examined the risk of PPH due to SSRIs. 19, 33 One study from the US showed an increase in PPH associated with SSRI use [rate ratio 1.47, 95% CI 1.33, 1.62], 19 whereas another study from Ontario, Canada, yielded a modestly elevated increase in risk of PPH in the primary analysis [odds ratio of 1.30, 95% CI 0.98, 1.72]. 32 The Ontario study focused on SSRI effects alone and excluded all women at increased risk of bleeding due to medical conditions (such as alcoholism, liver disease, and thrombocytopenia) or concomitant exposure to other drugs (such as antiplatelet agents). In our study, antidepressant (mainly SSRI) use was associated with an increase in PPH [rate ratio 1.48 The frequency of antidepressant drug use in pregnancy in our study was approximately 1.8% among controls. This relatively low frequency is consistent with population rates of SSRI use for the period 1998-2009 34 and explains the small population attributable fraction (<1%) for PPH estimated in our study. On the other hand, some studies have documented rates of SSRI use as high as 7% and even 13%. 15, 16 Nevertheless, even such frequent use of SSRI's would only explain about 3-6% of PPH because of the relatively modest effect of antidepressants on PPH (rate ratio 1.48, Table 3 ). Although these low population attributable fractions suggest that SSRI use is unlikely to explain increases in population rates of PPH, the consistent findings of an approximately 40% relative increase in the risk of PPH among SSRI users is clinically relevant (absolute increase of 1.8 per 100 given a PPH rate of 4.5%).
19,33
Our study did not show an increased risk of PPH among women with asthma, and those using betaagonists or aspirin. Although beta-agonists have not been directly implicated in the occurrence of PPH, some evidence suggests that women with asthma have higher rates of antepartum and PPH. [35] [36] [37] [38] Studies of low-dose aspirin have yielded inconsistent results, with some studies showing an increase in PPH 18 and others showing no effect despite an increase in bleeding time; 39 a Cochrane review concluded that lowdose aspirin use in pregnancy does not increase the risk of PPH. 40 Our concern with medication use and drug and other interactions arose because of reports of increases in upper gastrointestinal bleeding associated with SSRIs use in combination with NSAIDs/Cox-2 inhibitors, anticoagulants, and antiplatelet agents or among subjects with liver failure or cirrhosis. 31, 32 Drug interactions involving SSRIs and antiplatelet drugs resulting in excessive bleeding have also been observed among patients with acute myocardial infarction. 20 Similarly, serotonin-modulating drugs have been shown to increase fatality rates in cases of intra-cerebral haemorrhage when administered along with warfarin. 21 In our analyses, concurrent exposure to antidepressants, aspirin, beta-agonists, and thrombocytopenia increased the risk of PPH but these effects were not statistically significant. However, postpartum bleeding is different from gastrointestinal, myocardial, and intra-cerebral bleeding insofar as such blood loss is a normal and routine part of childbirth. Physiologic mechanisms that act to reduce PPH (e.g. contraction of the uterus) work in a setting of high vascularity and include factors very different from those associated with other types of bleeding. On the other hand, we cannot exclude the possibility that our negative results occurred because of misclassification of women who used aspirin and NSAIDs, or because of inaccuracies in the identification of women with co-morbidity. Another concern relates to the relatively small numbers of women with concurrent exposure to more than one drug/ co-morbidity (Tables 2,4 ).
The strengths of our study include the comprehensive nature of our data source, which included information on PPH, clinical, and other risk factors for PPH and prescription drug use. Exposure misclassification with regard to drugs such as antidepressants would have been minimal, as the accuracy of the information in our data source has been previously validated. 23, 24 Estimates of association between maternal and obstetric factors and PPH in this study were also similar to those obtained from studies using hospitalisation data from Canada excluding Québec (including the protective effect of caesarean delivery on PPH, which is a consequence of the different definitions of PPH used for vaginal vs. caesarean deliveries). Finally, our 'population-based' case-control study within a primary study base minimised the challenges associated with control selection since selection of controls representative of the study base could be ensured through incidence density sampling of a clearly defined population. 26 Limitations of our study included problems typical of studies based on large linked databases. Also, difficulties in ascertaining blood loss during childbirth make the diagnosis of PPH challenging. However, the absolute rate of PPH was not a primary concern in our study, which was focused on PPH rates among users vs. nonusers of specific drugs and on the effect of adjustment for such drug use on temporal changes in PPH rates. Testing of the study hypotheses related to aspirin and NSAIDs should be regarded as preliminary, as our data source exclusively recorded medications dispensed by prescription. Substantial misclassification of aspirin and NSAID use in our study was therefore inevitable. Although our study size was large, the small numbers of women who were concurrently exposed to more than one drug/ co-morbidity meant that the study lacked adequate statistical power for evaluating the interactions of interest. Similarly, small numbers precluded separate assessment of the effects of antidepressants by subtype (69% of recent use involved SSRIs). All pregnancies in the study population were included without adjustment for the potential nonindependence of observations because of multiple deliveries to the same woman. Since the study population included 6378 cases of PPH among a total of 6248 women, this bias was not expected to significantly alter the precision of our estimates. Finally, the absence of procedure codes in a significant fraction of records prevented us from studying severe PPH. This limitation also prevented us from including operative vaginal delivery as a variable in our models.
Conclusions
Antidepressant use was associated with an increased risk of PPH and atonic PPH, whereas thrombocytopenia was associated with an increased risk of PPH. Other medications, such as aspirin and NSAIDs, and co-morbidity such as liver disease, were not significantly associated with PPH, and no statistically significant drug and related interactions were observed (although the study size limited our ability to assess such interactions). The results suggest that such drug use and drug interactions are unlikely to contribute to any substantial increase in atonic PPH. Other studies are needed to corroborate out findings and also to examine other novel hypotheses as potential explanations for the recent increase in atonic PPH.
